<DOC>
	<DOCNO>NCT03015844</DOCNO>
	<brief_summary>This expand access protocol/compassionate use single institution study design determine palliative benefit toxicity 131I-MIBG patient progressive neuroblastoma metastatic pheochromocytoma eligible therapy higher priority . Response rate , toxicity , time progression death evaluate .</brief_summary>
	<brief_title>A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy Patients With Refractory Neuroblastoma Metastatic Pheochromocytoma</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Pheochromocytoma</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<criteria>Diagnosis : Relapsed/Refractory neuroblastoma , original diagnosis make histologically elevated urine catecholamine abnormal tumor cell bone marrow OR relapsed/refractory pheochromocytoma . Disease status : Progressive disease time ( defined new lesion increase size &gt; 25 % preexist disease ) , failure respond standard therapy . Patients must evidence MIBG uptake tumor ≥ one site within 6 week prior entry study subsequent intervening therapy Prior therapy : A minimum two week since elapse since chemotherapy cause myelosuppression . It must minimum three month since receive radiation follow field : craniospinal , total abdominal , whole lung , total body irradiation . For site radiation , least 2 week elapse . For patient receive radiation site MIBGavid disease within two month study entry , biopsy confirmation residual active disease require , positive bone marrow sufficient . At least 7 day elapse since completion therapy biologic agent least 3 halflives elapse since therapy monoclonal antibody . No cytokine therapy may give within 24 hour receive 131IMIBG . Patients may receive prior MIBG therapy , provide demonstrated response stable disease initially , progressive disease occur least 35 day follow treatment . Organ function : ANC &gt; 500/uL , platelet &gt; 20,000/uL transfusion allow . Bilirubin ≤2x ULN , AST/ALT ≤10x ULN.Serum Creatinine ≤2x ULN OR 24hour creatinine clearance OR GFR ≥60ml/min/1.73m2 . Normal lung function demonstrate dyspnea , exercise intolerance oxygen requirement . Oxygen saturation ≥94 % room air . No clinically significant cardiac dysfunction ejection fraction ≥45 % echocardiogram . Stem cell : Patients must minimum 2.0 x106/kg viable CD34+ peripheral blood stem cell reinfusion follow 131IMIBG . An additional backup 2.0x106/kg CD34+ cell recommend require . Life expectancy longer 8 week , Karnofsky Lansky performance status ≥ 50 % Pregnant lactating patient Disease organ system would compromise patient 's ability participate study , include hemodialysis . Significant organ impairment discuss Principal Investigator prior study entry Patients active grade 34 infection , define NCI CTCAE V4.0 . Patients know MBIGavid brain parenchymal disease ( leptomeningeal skull base metastasis eligible ) . In patient metastatic pheochromocytoma , urinalysis must preform prior study enrollment . If proteinuria present , 24 hour urine must collect total protein determine . If 24hour urine protein institutional upper limit normal , patient exclude .</criteria>
	<gender>All</gender>
	<minimum_age>365 Days</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>MIBG</keyword>
	<keyword>131I-MIBG</keyword>
	<keyword>relapse</keyword>
	<keyword>neuroblastoma</keyword>
	<keyword>pheochromocytoma</keyword>
</DOC>